Which is the role for inherited TRβ mutation in human thyroid carcinogenesis?

Weinert, Letícia Schwerz; Ceolin, Lucieli; Romitti, Mírian; Camargo, Eduardo Guimarães; Maia, Ana Luiza Silva

doi:10.1590/s0004-27302012000200010

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When the dose of levothyroxine was increased, in those patients hyperthyroidism symptoms (tachycardia, anxiety) occurred, so levothroxine dose was decreased. In two cases, with the addition of T3 to the treatment TSH levels decreased to the normal range (17,18). There are also papers related with suppression of TSH with thyroid hormone analogs, such as triiodothyroacetic acid (TRIAC) in RTH (19,20).…”

Section: Discussionmentioning

confidence: 99%

Thyroid hormone resistance in two patients with papillary thyroid microcarcinoma and their BRAFV600E mutation status

Karaköse

Çalışkan

Arslan

et al. 2015

Arch. Endocrinol. Metab.

View full text Add to dashboard Cite

Resistance to thyroid hormone (RTH) is a rare autosomal dominant hereditary disorder. Here in, we report two patients with RTH in whom differentiated thyroid cancer was diagnosed. Two patients were admitted to our clinic and their laboratory results were elevated thyroid hormone levels with unsuppressed TSH. We considered this situation thyroid hormone resistance in the light of laboratory and clinical datas. Thyroid nodule was palpated on physical examination. Thyroid ultrasonography showed multiple nodules in both lobes. Total thyroidectomy was performed. The pathological findings were consistent with papillary thyroid microcarcinoma. BRAFV600E mutation analysis results were negative. RTH is very rare and might be overlooked. There is no consensus on how to overcome the persistently high TSH in patients with RTH and differentiated thyroid cancer (DTC). Further studies are needed to explain the relationship between RTH and DTC which might be helpful for the treatment of these patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Thyroid hormone resistance in two patients with papillary thyroid microcarcinoma and their BRAFV600E mutation status

Karaköse

Çalışkan

Arslan

et al. 2015

Arch. Endocrinol. Metab.

View full text Add to dashboard Cite

show abstract

“…However, lack of functions of THRs secondary to altered genes was demonstrated in human cancer (7,13,14). In particular, the THRB mutation was shown to be common in thyroid diseases and human cancer including breast cancer (13,15,16), and LOH was detected in human prostate cancer, esophageal cancer and endocrine tumors of the cervix (8)(9)(10)(11). These suggest that THRB can act as a tumor suppressor.…”

Section: Discussionmentioning

confidence: 99%

Loss of Heterozygosity in Thyroid Hormone Receptor Beta in Invasive Breast Cancer

Ling

Yang

et al. 2015

Tumori

View full text Add to dashboard Cite

show abstract

“…Thyroid hormone is also able to block oncogenic Ras-mediated proliferation and transcriptional induction of cyclin D1 in neuroblastoma cells (29). Moreover, it has been shown that thyroid carcinogenesis may be associated with mutations in thyroid hormone receptor β (TRβ) gene (30). The conversion of the pro-hormone T4 into the biologically active hormone T3 is catalyzed by iodothyronine deiodinases (type 1 and type 2) (15).…”

Section: Discussionmentioning

confidence: 99%

mRNA expression pattern of retinoic acid and retinoid X nuclear receptor subtypes in human thyroid papillary carcinoma

Macejova

Galbavý²,

Podoba³

et al. 2013

Oncology Reports

View full text Add to dashboard Cite

Retinoids have shown potential for the inhibition of tumour growth and progression. The objective of this study was to investigate retinoic acid nuclear receptor subtypes RAR/RXR and iodothyronine 5'-deiodinase, type I expression pattern in papillary thyroid tumour tissue of 26 patients in order to compare with those of the non-neoplastic thyroid tissue of the corresponding patients. The expression of selected parameters mRNA was examined by semi-quantitative RT-PCR. Papillary thyroid carcinoma (PTC) expressed RXRγ, when compared to non-neoplastic thyroid tissues of the corresponding patients that were lacking expression of RXRγ or its expression was very low. Moreover, we found significantly increased expression of RARα and RARγ in the overall group of PTC. This increase was detected in cases with positive lymph node metastasis (LNM), but not in cases with negative LNM. RARβ was significantly reduced in the subgroup of classic variant (CV). We also detected absence or significantly lower expression of hDIO1 mRNA in tumour tissue when compared to non-neoplastic tissue in both overall PTC cases and in the CV subgroup. However, the significantly decreased levels of hDIO1 mRNA were detected in cases with negative LNM but not in cases with positive LNM when compared to corresponding non-tumour tissue in both overall PTC cases and in the CV subgroup. Differences in RAR and RXR subtype mRNA expression patterns in various PTCs may contribute to the immunochemistry data available, and may thus find exploitation in clinical oncology, particularly in the differential diagnosis of thyroid neoplasms.

show abstract

Which is the role for inherited TRβ mutation in human thyroid carcinogenesis?

Cited by 3 publications

References 0 publications

Thyroid hormone resistance in two patients with papillary thyroid microcarcinoma and their BRAFV600E mutation status

Thyroid hormone resistance in two patients with papillary thyroid microcarcinoma and their BRAFV600E mutation status

Loss of Heterozygosity in Thyroid Hormone Receptor Beta in Invasive Breast Cancer

mRNA expression pattern of retinoic acid and retinoid X nuclear receptor subtypes in human thyroid papillary carcinoma

Contact Info

Product

Resources

About